Explore commercial-grade peptide APIs manufactured under rigorous cGMP environments with batch-certified purity, HPLC validation, and comprehensive COA documentation.
An authoritative technical review on the 37-amino acid human cathelicidin (CAMP) derivative, its broad-spectrum biophysical mechanisms, and chemical manufacturing thresholds.
Human cathelicidin antimicrobial peptide LL-37 (sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) represents the lone member of the cathelicidin family naturally synthesized in humans. Expressed by mucosal epithelial cells, neutrophils, and epidermal keratinocytes as an inactive 18-kDa pro-peptide (hCAP18), it undergoes extracellular enzymatic cleavage by proteinase 3 to liberate the biologically active 37-amino acid carboxyl-terminal amphipathic peptide. In commercial biopharmaceutical manufacturing, LL-37 has risen to the forefront of global clinical pipelines due to its dual functional profile: direct bactericidal eradication via non-receptor-mediated membrane disruption and complex immunomodulatory orchestration across multiple host signaling pathways.
From an structural perspective, LL-37 exhibits an unstructured, flexible conformation in aqueous solutions at physiological concentrations. However, upon exposure to negatively charged bacterial outer membranes or hydrophobic cell-membrane mimetic environments (such as trifluoroethanol or lipid micelles), the molecule undergoes a rapid transition into a well-defined amphipathic α-helix. The segregation of its positively charged lysine and arginine residues on one face of the cylinder and hydrophobic phenylalanine, leucine, and isoleucine residues on the opposing face creates an electrostatic-hydrophobic dipole. This conformational architecture permits catastrophic permeabilization of bacterial phospholipid bilayers via the toroidal pore or carpet mechanism, mitigating the traditional pathways that drive antimicrobial resistance (AMR).
When pharmaceutical, medical device, and high-end cosmeceutical developers source LL-37 peptide bulk powder, raw purity percentages alone do not provide regulatory viability. Sourcing directors and analytical QA/QC departments evaluate a multi-layered panel of physical, chemical, and microbiological indices to ensure batch-to-batch bioequivalence and formulation stability.
| Analytical Parameter | Target Specification | Analytical Methodology | Procurement Significance |
|---|---|---|---|
| Chemical Purity | ≥ 98.0% – 99.0% | Reversed-Phase HPLC (C18 / C4, UV 214nm) | Eliminates deletion peptides, truncations, and stereoisomeric D-amino acid impurities. |
| Identity Confirmation | 4493.3 ± 1.0 Da | High-Resolution ESI-MS / MALDI-TOF | Validates complete sequence synthesis without missing basic or aromatic residues. |
| Net Peptide Content | 75.0% – 85.0% | Elemental Nitrogen Analysis / Quantitative AAA | Calculates exact stoichiometric API dosing versus salt counter-ions and bound hydration water. |
| Residual Counter-Ion | TFA ≤ 0.5% (or Acetate conversion ≥ 98%) | Ion Chromatography (IC) with Suppressed Conductivity | Removes cytotoxic trifluoroacetate adducts for clinical in-vivo, cell culture, and topical safety. |
| Bacterial Endotoxin | ≤ 5.0 EU/mg (Injectable Grade ≤ 0.1 EU/mg) | Kinetic Turbidimetric LAL Assay (USP <85>) | Prevents pyrogenic reactions in wound dressing coatings, systemic injections, and animal models. |
| Residual Organic Solvents | DMF, DCM, Piperidine < ICH Limits | Headspace Gas Chromatography (GC-MS) | Ensures compliance with ICH Q3C guidelines for toxic synthetic reagent residues. |
Discover how industrialized high-throughput solid-phase synthesis platforms and integrated chemical precursors overcome legacy Western peptide cost bottlenecks.
Utilizing high-capacity, distributed PLC-controlled peptide synthesizers with real-time UV deprotection monitoring. Real-time feedback loops adjust coupling times and temperature profiles automatically, ensuring that difficult hydrophobic sequences across LL-37 are coupled with greater than 99.2% single-step efficiency.
Hangzhou-based raw material ecosystems supply domestically produced, pharma-grade Fmoc-amino acids, coupling reagents (HATU, HBTU, DIC, OxymaPure), and specialized super-acid-labile CTC and Wang resins. This internal backward integration insulates global buyers from geopolitical supply chain chokepoints and raw material surcharges.
Multi-ton industrial peptide synthesis capacity equipped with automated solvent recycling distillation columns. By reclaiming up to 88% of synthesis-grade N,N-dimethylformamide (DMF) and acetonitrile, the facility dramatically slashes carbon footprints and manufacturing overhead, passing substantial savings to enterprise buyers.
The historical challenge of procuring therapeutic-grade LL-37 in large volumes (hundreds of grams to multi-kilograms) has been rooted in the commercial economics of solid-phase peptide synthesis. In European and North American manufacturing houses, manual intervention, high compliance overheads, and fragmented raw material sourcing have driven the spot price of research-grade LL-37 to upwards of $80 to $150 per milligram. For commercial wound dressing manufacturers or cosmeceutical skin barrier developers, such price points render formulation unit economics completely unfeasible.
The Hangzhou manufacturing complex alters this paradigm through deep Industrial Automation 4.0. Cleanroom facilities operating under strict ISO 9001 and cGMP-aligned quality systems incorporate continuous preparative DAC (Dynamic Axial Compression) columns (up to 300mm–600mm internal diameter). These systems perform single-pass chromatographic fractionation with unprecedented peak resolution, separating closely migrating des-Arg and des-Leu deletion side-products from the native LL-37 target. Furthermore, proprietary counter-ion exchange columns allow the continuous displacement of toxic trifluoroacetate (TFA) ions with pharmaceutical-preferred acetate or hydrochloride salts without degrading the peptide via hydrolytic cleavage.
Detailed mapping of LL-37 demand drivers across biopharma pipelines, chronic wound healing regimes, medical device functionalization, and cosmetic skin resilience formulations.
LL-37 promotes re-epithelialization by binding to Formyl Peptide Receptor-Like 1 (FPRL1/FPR2) and inducing EGFR transactivation. It accelerates keratinocyte migration, stimulates vascular endothelial cell tubulogenesis, and revascularizes hypoxic ulcer beds where healing has stalled.
Unlike conventional antibiotics that fail against dense extracellular polymeric substances (EPS), LL-37 penetrates recalcitrant biofilms created by Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), degrading the matrix at sub-MIC levels.
Widely integrated into next-generation post-procedure recovery serums and barrier cremes. LL-37 neutralizes inflammatory bacterial flagellin and lipopolysaccharides (LPS), suppresses erythema, stimulates tight-junction claudin synthesis, and accelerates stratum corneum repair.
Immobilized via covalent silanization or layer-by-layer polymer deposition onto titanium orthopedic implants, silicone Foley catheters, and vascular grafts. Provides stable, contact-killing surface biocidal properties that prevent nosocomial catheter-related bloodstream infections.
A distinctive pharmacological attribute of LL-37 over typical synthetic biocides is its ability to bind bacterial lipopolysaccharide (LPS). Gram-negative bacterial lysis by standard bactericidal agents frequently releases colossal quantities of free endotoxin into the systemic circulation or local wound matrix, triggering severe Toll-like Receptor 4 (TLR4) cascade activation, downstream NF-κB translocation, and lethal septic cytokine storms (TNF-α, IL-1β, IL-6). LL-37 directly complexes with lipid A domains of LPS through its high-density cationic α-helical array, effectively neutralizing its endotoxic potential. Pharmaceutical developers formulating treatments for acute lung injury (ALI), ARDS, and systemic sepsis leverage this exact mechanism to prevent tissue destruction during broad-spectrum bactericidal clearance.
A strategic framework for procurement directors, CRO heads, and technical sourcing committees to evaluate manufacturer capabilities and regulatory dossiers.
Never accept raw purity values without ion quantification. Residual trifluoroacetate forms stable ionic salts with basic lysine/arginine residues on LL-37. In cell viability assays, residual TFA can induce false cellular toxicity. Ensure the supplier provides documented IC chromatograms demonstrating complete conversion to acetate (<1% TFA).
Demand deconvolution electrospray ionization MS (ESI-MS) spectra. Because LL-37 carries multiple charges (+3 to +8 ions), low-resolution mass spectrometers may miss truncated deletion sequences occurring within the center of the molecule. Multi-charge peak resolution guarantees absolute monoisotopic molecular weight matching.
LL-37 is susceptible to hygroscopic clumping if the final freeze-drying cycle is not meticulously staged. Sourcing partners must confirm that primary and secondary drying curves have reduced residual moisture below 3.0%, generating a uniform, instantly reconstitutable lyophilized white powder under sterile argon headspace capping.
Critical answers to questions asked by procurement teams, formulation chemists, and technical project managers.
Standard lead times for custom synthesis and purification of 10g to 500g of HPLC-certified ≥98% LL-37 peptide range from 2 to 3 weeks. Multi-kilogram production runs under cGMP-aligned conditions require approximately 4 to 6 weeks, which includes full analytical release testing (MS, HPLC, residual counter-ion, endotoxin, and trace solvent screening).
Trifluoroacetic acid (TFA) is the standard cleavage agent in Fmoc solid-phase synthesis. However, TFA is intrinsically cytotoxic to human fibroblasts and keratinocytes at micromolar thresholds. For wound healing hydrogels, cosmetic lotions, or preclinical animal injections, converting LL-37 to an acetate or hydrochloride salt form eliminates cytotoxic artifacts and complies with pharmacopeial safety regulations.
Lyophilized LL-37 should be reconstituted in sterile, deoxygenated ultrapure water or 0.1% sterile acetic acid to prepare a concentrated stock solution (e.g., 1–5 mg/mL) before diluting into physiological buffers like PBS or culture medium. Due to its hydrophobic face, direct reconstitution into high-salt alkaline buffers can provoke premature aggregation or precipitation.
Cost efficiency stems from scale, automation, and upstream vertical integration. By manufacturing raw Fmoc amino acids and coupling reagents in-house, deploying continuous automated synthesis reactors, and reclaiming process solvents via automated closed-loop distillation, our factory cuts chemical material costs by over 45% while achieving analytical purity equal or superior to Western contract manufacturers.
Discover our broader catalog of synthetic peptides, including mitochondrial modulators, neuroactive factors, and copper complexes produced at commercial multi-kilogram scale.
Thin